NTRA250117P85000
- 0.40
- 0.000.00%
Natera Newsroom
Investors Bid Natera (NASDAQ:NTRA) up US$2.4b Despite Increasing Losses YoY, Taking Five-year CAGR to 38%
Positive Outlook for Natera: Buy Rating Driven by Strong Revenue Performance and Strategic Developments
Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $174
Craig-Hallum Sticks to Their Buy Rating for Natera (NTRA)
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Insider Sale: Director at $NTRA (NTRA) Sells 288 Shares
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Natera Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $180
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)
Natera's (NASDAQ:NTRA) Investors Will Be Pleased With Their Enviable 353% Return Over the Last Five Years
When Will Natera, Inc. (NASDAQ:NTRA) Breakeven?
Court Grants Natera's Request to Include Additional Patent in Its Lawsuit Against NeoGenomics
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $195
Express News | Natera Inc : TD Cowen Raises Target Price to $195 From $175
Express News | Natera Inc : Guggenheim Raises Target Price to $170 From $165
Insider Sale: EXECUTIVE CHAIRMAN of $NTRA (NTRA) Sells 5,300 Shares
Natera(NTRA.US) Officer Sells US$26.52 Million in Common Stock
Express News | Form 144 | Natera(NTRA.US) Director Proposes to Sell 26.63 Million in Common Stocks
Natera Is Maintained at Overweight by JP Morgan